33
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Strengthening the Skin with Topical Delivery of Keratinocyte Growth Factor-1 Using a Novel DNA Plasmid

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Fragile skin, susceptible to decubitus ulcers and incidental trauma, is a problem particularly for the elderly and for those with spinal cord injury. Here, we present a simple approach to strengthen the skin by the topical delivery of keratinocyte growth factor-1 (KGF-1) DNA. In initial feasibility studies with the novel minimalized, antibiotic-free DNA expression vector, NTC8385-VA1, the reporter genes luciferase and enhanced green fluorescent protein were delivered. Transfection was documented when luciferase expression significantly increased after transfection. Microscopic imaging of enhanced green fluorescent protein–transfected skin showed green fluorescence in hair follicles, hair shafts, and dermal and superficial epithelial cells. With KGF-1 transfection, KGF-1 mRNA level and protein production were documented with quantitative reverse transcriptase–polymerase chain reaction and immunohistochemistry, respectively. Epithelial thickness of the transfected skin in the KGF group was significantly increased compared with the control vector group (26 ± 2 versus 16 ± 4 µm) at 48 hours ( P = 0.045). Dermal thickness tended to be increased in the KGF group (255 ± 36 versus 162 ± 16 µm) at 120 hours ( P = 0.057). Biomechanical assessment showed that the KGF-1–treated skin was significantly stronger than control vector–transfected skin. These findings indicate that topically delivered KGF-1 DNA plasmid can increase epithelial thickness and strength, demonstrating the potential of this approach to restore compromised skin.

          Related collections

          Most cited references47

          • Record: found
          • Abstract: found
          • Article: not found

          Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo.

          Low efficiencies of nonviral gene vectors, the receptor-dependent host tropism of adenoviral or low titers of retroviral vectors limit their utility in gene therapy. To overcome these deficiencies, we associated gene vectors with superparamagnetic nanoparticles and targeted gene delivery by application of a magnetic field. This potentiated the efficacy of any vector up to several hundred-fold, allowed reduction of the duration of gene delivery to minutes, extended the host tropism of adenoviral vectors to nonpermissive cells and compensated for low retroviral titer. More importantly, the high transduction efficiency observed in vitro was reproduced in vivo with magnetic field-guided local transfection in the gastrointestinal tract and in blood vessels. Magnetofection provides a novel tool for high throughput gene screening in vitro and can help to overcome fundamental limitations to gene therapy in vivo.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Design and gene delivery activity of modified polyethylenimines.

            The polycation polyethylenimine (PEI) has recently been widely employed for the design of DNA delivery vehicles. Gene delivery using PEI involves condensation of DNA into compact particles, uptake into the cells, release from the endosomal compartment into the cytoplasm, and uptake of the DNA into the nucleus. Particularly for in vivo gene delivery, optimal coordination and timing between DNA complexation for protection of the DNA from nucleases and the disassembly of the complexes is essential. For in vivo application, DNA complexes have to pass a variety of anatomical and physiological barriers, and an environment of biological fluids and extracellular matrix before reaching their targets. Furthermore, targeted gene delivery is seriously hampered by non-specific interactions with non-target cells. Strategies have been developed to protect transfection complexes from non-specific interactions and to increase target specificity and gene expression.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Ultrasound-mediated transdermal drug delivery: mechanisms, scope, and emerging trends.

              The use of ultrasound for the delivery of drugs to, or through, the skin is commonly known as sonophoresis or phonophoresis. The use of therapeutic and high frequencies of ultrasound (≥0.7MHz) for sonophoresis (HFS) dates back to as early as the 1950s, while low-frequency sonophoresis (LFS, 20-100kHz) has only been investigated significantly during the past two decades. Although HFS and LFS are similar because they both utilize ultrasound to increase the skin penetration of permeants, the mechanisms associated with each physical enhancer are different. Specifically, the location of cavitation and the extent to which each process can increase skin permeability are quite dissimilar. Although the applications of both technologies are different, they each have strengths that could allow them to improve current methods of local, regional, and systemic drug delivery. In this review, we will discuss the mechanisms associated with both HFS and LFS, specifically concentrating on the key mechanistic differences between these two skin treatment methods. Background on the relevant physics associated with ultrasound transmitted through aqueous media will also be discussed, along with implications of these phenomena on sonophoresis. Finally, a thorough review of the literature is included, dating back to the first published reports of sonophoresis, including a discussion of emerging trends in the field. Copyright © 2011 Elsevier B.V. All rights reserved.
                Bookmark

                Author and article information

                Journal
                Mol Ther
                Mol. Ther
                Molecular Therapy
                Nature Publishing Group
                1525-0016
                1525-0024
                April 2014
                17 January 2014
                18 February 2014
                1 April 2014
                : 22
                : 4
                : 752-761
                Affiliations
                [1 ]Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chinese PLA General Hospital , Beijing, China
                [2 ]Department of Surgery and Hendrix Burn/Wound Laboratory, The Johns Hopkins University School of Medicine , Baltimore, Maryland, USA
                [3 ]Department of Medicine, The Johns Hopkins University School of Medicine , Baltimore, Maryland, USA
                [4 ]Department of Pathology, The Johns Hopkins University School of Medicine , Baltimore, Maryland, USA
                [5 ]GenArmor , Winston Salem, North Carolina, USA
                [6 ]Nature Technology Corporation , Lincoln, Nebraska, USA
                Author notes
                [* ]Section of Surgical Sciences, Room 5C, A Building, Johns Hopkins Bayview Medical Center, 4940 Eastern Avenue, Baltimore, MD 21224, USA. E-mail: jharmon2@ 123456jhmi.edu
                []

                The first two authors contributed equally to this workiple as first authors.

                []

                A.M.A. and D.J.R. contributed equally to this work as second authors.

                Article
                mt20142
                10.1038/mt.2014.2
                3982499
                24434934
                5d95fc59-402a-4f2c-b111-aee96412d4ab
                Copyright © 2014 The American Society of Gene & Cell Therapy

                This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

                History
                : 21 October 2013
                : 23 December 2013
                Categories
                Original Article

                Molecular medicine
                Molecular medicine

                Comments

                Comment on this article